Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.37 |
| ▸ | AKT1 | P31749 | 3/20 | 0.36 |
| ▸ | AKT2 | P31751 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.35 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658869 | 0.89 | HDAC1 (0.36) | IGF1RAKT1AKT2HDAC1HDAC6 | |
| SCHEMBL3352924 | 0.88 | HDAC1 (0.42) | IGF1RHDAC1HDAC6INSRHDAC2 | |
| SCHEMBL658594 | 0.87 | HDAC6 (0.34) | HDAC1HDAC6KDM1AHDAC2HDAC3 | |
| SCHEMBL3354974 | 0.85 | HDAC1 (0.37) | AKT1AKT2HDAC1HDAC6HDAC2 | |
| SCHEMBL3357617 | 0.82 | CCNE1 (0.40) | AKT1AKT2HDAC1HDAC6KDM1A | |
| SCHEMBL701224 | 0.82 | IGF1R (0.47) | IGF1RHDAC1HDAC6INSRHDAC2 | |
| SCHEMBL3357009 | 0.82 | HDAC1 (0.38) | AKT1AKT2HDAC1HDAC6HDAC2 | |
| SCHEMBL658275 | 0.82 | AKT1 (0.36) | IGF1RAKT1AKT2HDAC1KDR | |
| SCHEMBL197875 | 0.80 | F2RL3 (0.39) | AKT1AKT2HDAC1HDAC6HDAC2 | |
| SCHEMBL3356590 | 0.79 | AKT1 (0.42) | AKT1AKT2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198299-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-06-12 | — | — | US | claimed |
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | IGF1R 1912/4885AKT1 1338/4885AKT2 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.